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Background: Toll-like receptors (TLRs) form an essential part of the innate immune system, which plays a
fundamental role in rapidly and effectively controlling infections and initiating adaptive immunity. There are no
published data concerning the importance of polymorphisms of TLRs in conditioning susceptibility to influenza or
the severity of the disease. The aim of this study was to evaluate whether selected polymorphisms of TLR2, TLR3
and TLR4 influence the incidence and clinical picture of pandemic A/H1N1/2009 influenza.
Results: The study involved 272 healthy children attending our Emergency Room for influenza-like illness (ILI),
including 51 (18.8%) with pandemic A/H1N1/2009 influenza as revealed by real-time polymerase chain reaction, and
164 healthy controls examined after minor surgery. Genomic DNA was extracted from whole blood samples and
five single-nucleotide polymorphisms (SNPs) were studied: TLR2 rs5743708, TLR3 rs5743313, TLR3 rs5743315, TLR4
rs4986790 and TLR4 rs4986791. The TLR3 rs5743313/CT polymorphism was found in all of the children with
pneumonia and influenza infection, but in a significantly smaller number of those with A/H1N1/2009 influenza
without pneumonia (<0.0001). TLR2, TLR3 rs5743315/AC and TLR4 polymorphisms were equally distributed in all of
the groups regardless of the presence of the pandemic A/H1N1/2009 virus and clinical diagnosis. Viral load was
comparable in all of the study groups.
Conclusions: There is a close relationship between the presence of TLR3 rs5743313/CT and an increased risk of
pneumonia in children infected by the pandemic A/H1N1/2009 influenza virus.
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Toll-like receptors (TLRs) are a family of transmem-
brane proteins expressed on many cells, including den-
dritic and natural killer cells, macrophages and the cells
of the respiratory epithelium. They form an essential
part of the innate immune system, which plays a funda-
mental role in rapidly and effectively controlling infec-
tions and initiating adaptive immunity [1-8]. The central
role of TLR activation in both innate and adaptive im-
mune responses is demonstrated by the fact that TLR
polymorphisms influence susceptibility to a number of* Correspondence: nicola.principi@unimi.it
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reproduction in any medium, provided the orviral pathogens as well as the severity of the diseases
they cause [9-14].
It has been shown that TLR3 and TLR7 make the
main contribution to innate defences against influenza
viruses [15,16], but there are few published data con-
cerning the importance of polymorphisms of these and
other TLRs in conditioning susceptibility to influenza or
the severity of the disease [17,18]. However, such infor-
mation is important because it could allow the identifi-
cation of subjects for whom specific preventive and
therapeutic interventions should be planned in order to
reduce the clinical and socio-economic impact of influ-
enza infection. Moreover, a knowledge of how innate
immunity confronts influenza viruses could contributel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cines and drugs to prevent and treat the disease.
An A/H1N1 quadruple reassortant influenza virus
(A/H1N1/2009) of swine origin has recently arisen
from an A/H1N1 influenza virus subtype that was
already endemic in humans [19]. The aim of this study
was to evaluate whether selected polymorphisms of
TLR2, TLR3 and TLR4 (chosen from among those
previously associated with modified signalling function
and a greater susceptibility to presumed or demon-
strated infection) influence the incidence and clinical
picture of the disease caused by this virus.
Results
The study involved 436 prospectively and consecutively
enrolled children: 272 with influenza-like illness (ILI),
including 51 (18.8%) who were positive for pandemic
A/H1N1/2009 virus, and 164 healthy controls. None of
the blood cultures of the children with ILI was positive
for bacteria. Table 1 shows the demographic and clinical
characteristics of the children in the three groups. There
were no between-group differences in terms of gender,
race, age distribution, the number of siblings, exposure to
passive smoking, day care or school attendance, or previous
pneumococcal and/or pandemic influenza vaccination.
Moreover, the distribution of the clinical diagnoses and theTable 1 Demographic and clinical characteristics of the study
Characteristics A/H1N1/2009-positive c
admitted because of ILI
Males, No. (%) 27 (52.9)
Caucasians, No. (%) 51 (100.0)
Mean age ± SD, yrs 3.16 ± 3.46
Age groups, No. (%)
<2 years 5 (9.8)
2-5 years 44 (86.3)
>5 years 2 (3.9)
Median number of siblings (range) 1 (0–4)
Exposure to passive smoking, No. (%) 15 (29.4)
Day care or school attendance, No. (%) 49 (96.1)
Previous pneumococcal vaccination, No. (%) 46 (90.2)




Common cold 15 (29.4)
Pharyngitis 14 (27.5)
Acute otitis media 4 (7.8)
Pneumonia 18 (35.4)
Minor surgical problem NA
Hospitalised at enrolment, No. (%) 18 (35.4)
ILI: influenza-like illness; NA: not applicable; SD: standard deviation. Percentages inrates of hospitalisation were similar in both etiological
groups of patients with ILI. All of the patients with ILI
symptoms and a diagnosis of pneumonia were hospitalised;
all of the others were discharged.
Table 2 shows the genotype frequency of the selected
TLR polymorphisms in the study population as a whole.
There was no significant difference in their frequency
between the children who were positive or negative for
pandemic A/H1N1/2009 influenza, or between either of
the etiological groups of children with ILI and the
healthy controls.
Table 3 shows the genotype frequency of the TLR
polymorphisms in the children who were positive for
A/H1N1/2009 influenza virus, by disease severity. The
TLR2, TLR3 rs5743315/AC and TLR4 polymorphisms
were equally distributed in the two groups regardless
of the clinical diagnosis, whereas the TLR3 rs5743313/CT
polymorphism was found in all of the children with pneu-
monia and influenza infection, but in a significantly
smaller number of those A/H1N1/2009 influenza with-
out pneumonia without pneumonia (<0.0001). Viral load
was comparable in all of the study groups.
Discussion
In this study, we found that the prevalence of selected




admitted because of ILI (n=221)
Healthy controls
(n=164)
109 (49.3) 85 (51.8)
221 (100.0) 164 (100.0)
3.43 ± 3.79 3.39 ± 3.88
28 (12.7) 15 (9.1)
182 (82.4) 140 (85.4)
11 (5.0) 9 (5.5)
1 (0–3) 1 (0–4)
69 (31.2) 43 (26.2)
210 (95.0) 158 (96.3)
199 (90.0) 143 (87.2)







parentheses. No significant between-group difference.












GG 49 (96.1) 218 (98.6) 161 (98.2)
GA 2 (3.9) 3 (1.4) 3 (1.8)
p-value, HWE 0.89 0.92 0.91
TLR3 rs5743313
CC 26 (51.0) 124 (56.1) 92 (56.1)
TT 4 (7.8) 12 (5.4) 9 (5.5)
CT 21 (41.2) 85 (38.5) 63 (38.4)
p-value, HWE 0.93 0.60 0.67
TLR3 rs5743315
CC 46 (90.2) 208 (94.1) 149 (90.9)
AC 5 (9.8) 13 (5.9) 15 (9.1)
p-value, HWE 0.71 0.65 0.54
TLR4 rs4986790
AA 46 (90.2) 202 (91.4) 148 (90.2)
AG 5 (9.8) 19 (8.6) 16 (9.8)
p-value, HWE 0.71 0.50 0.51
TLR4 rs4986791
CC 46 (90.2) 203 (91.9) 148 (90.2)
TT 0 (0.0) 1 (0.5) 0 (0.0)
CT 5 (9.8) 17 (7.6) 16 (9.8)
p-value, HWE 0.71 0.33 0.51
HWE: Hardy-Weinberg equilibrium; ILI: influenza-like illness; TLR: toll-like receptor. Percentages in parentheses. No significant between-group difference.
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in healthy children and in patients with ILI, regardless
of whether they were positive or negative for pandemic
A/H1N1/2009 influenza virus infection. This means
that the occurrence of influenza does not seem to depend
on these genetic variants. The same conclusion could be
drawn regarding the risk of superimposed bacterial infec-
tions, because the cultured blood of all of the children
with ILI was negative for bacteria at the time of diagno-
sis, regardless of the etiology of the disease. However, this
merits further study because blood cultures are not very
sensitive for the detection of bacteremia, and only
molecular methods can exclude co-infection with viral
and bacterial respiratory pathogens [20].
We found a close relationship between the presence of
the TLR3 rs5743313/CT polymorphism and an increased
risk of pneumonia in children infected by the pandemic
A/H1N1/2009 influenza virus. As the children with
pandemic A/H1N1/2009 influenza who were hospitalised
for pneumonia were similar to those with pandemic
A/H1N1/2009 influenza who were discharged from the
Emergency Room because their disease was milder,
this finding suggests that the TLR3 rs5743315/ACpolymorphism per se may play a role in conditioning
the risk of pneumonia in children infected by pandemic
A/H1N1 influenza virus. The fact that viral load was not
higher in the children with this genetic variation does not
modify this conclusion because viral load is not a reli-
able expression of the severity of viral illness. Viral load
declines over time and, because the respiratory secre-
tions used to evaluate it were not always collected at
the beginning of the disease, it may not correlate with
the clinical picture [21,22].
Although TLR3 is considered an essential part of the
innate immune system, it is abundantly expressed in
dendritic cells, recognises viral pathogens, and induces
interferon beta (IFN-b) production [7]. It is likely that
the antiviral effects of TLR3 signalling on influenza virus
infection are mediated by the stimulation of a variety of
cells (such as hematopoietic stem cells, monocyte-
derived dendritic cells, endothelial cells and NK cells) to
produce type I IFN, which subsequently inhibits viral
replication. However, whether it protects or not against
influenza viruses has not been precisely defined. In ex-
perimental animals, the administration of TLR3 agonists
is effective in reducing the damage caused by influenza
Table 3 Genotype frequency of toll-like receptor (TLRs) polymorphisms in children with pandemic A/H1N1 influenza




because of pneumonia (n=18)
A/H1N1/2009-positive children discharged with a
diagnosis other than pneumonia (n=33)
Frequency Viral load
(mean log10 cp/mL ± SD)
Frequency Viral load
(mean log10 cp/mL ± SD)
TLR2 rs5743708
GG 17 (94.4) 7.43 ± 1.30 32 (97.0) 7.06 ± 1.57
GA 1 (5.6) 3.88 1 (3.0) 8.29
p-value, HWE 0.90 0.93
TLR3 rs5743313
CC 0 (0.0)* NA 26 (78.8) 6.94 ± 1.45
TT 0 (0.0) NA 4 (12.1) 7.24 ± 2.42
CT 18 (100.0)* 7.23 ± 1.51 3 (9.1) 8.07 ± 1.33
p-value, HWE <0.001 <0.001
TLR3 rs5743315
CC 15 (83.3) 7.26 ± 1.66 31 (93.9) 7.12 ± 1.59
AC 3 (16.7) 7.10 ± 0.36 2 (6.1) 6.69 ± 1.25
p-value, HWE 0.70 0.86
TLR4 rs4986790
AA 16 (88.9) 7.12 ± 1.53 30 (90.9) 7.00 ± 1.56
AG 2 (11.1) 8.14 ± 1.41 3 (9.1) 8.01 ± 1.57
p-value, HWE 0.80 0.78
TLR4 rs4986791
CC 17 (94.4) 7.24 ± 1.56 29 (87.9) 7.00 ± 1.56
TT 0 (0.0) NA 0 (0.0) NA
CT 1 (5.6) 7.14 4 (12.1) 8.01 ± 1.57
p-value, HWE 0.90 0.71
HWE: Hardy-Weinberg equilibrium; NA: not available; TLR: toll-like receptor. Percentages in parentheses. *p<0.0001 vs A/H1N1/2009-positive children discharged
with a diagnosis other than pneumonia; no other significant between-group difference.
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adapted laboratory influenza A viruses and clinical
isolates from humans (including considerably virulent
strains with pandemic potential). Moreover, the induc-
tion of local pulmonary inflammation such as that
caused by TLR3 activation has been found to protect
against influenza infection in mice [25]. It has also been
found that TLR3 activation in the context of an influ-
enza virus infection leads to excess cytokine production
and inflammatory lung alterations that cause severe
tissue damage and reduce survival in TLR3-deficient
mice, [26]. The reasons given to explain these conflicting
findings include the type of virus used to infect the ani-
mals, viral load, the infected cell type, and the stage of
infection [27].
However, our data seem to suggest that, although TLR3
does not affect the occurrence of pandemic A/H1N1/
2009 influenza, it might favourably condition the clinical
course of the disease because the incidence of influenza-
related pneumonia was significantly higher in the childrenwith TLR3 polymorphisms than in those without. As the
polymorphism associated with a more severe course of
pandemic A/H1N1/2009 influenza (TLR3 rs5743313/CT)
is located near exon 4 (i.e. the gene region encoding
trans-membrane signal induction), it may play a signifi-
cant role in reducing the efficiency of the mechanisms
that recognise influenza virus, thus leading to cytokine
production and a reduction in immune defences that
favours more severe influenza. This hypothesis seems to
be supported by the findings that exon 4 in the gene of
TLR3 is very rich in tyrosine, a target of the tyrosine
kinase c-SRC, and that an association between TLR3
and c-SRC tyrosine kinase on endosomes is essential to
initiate antiviral signalling [28].
Associations between TLR3 polymorphisms and
human diseases have been frequently demonstrated.
Variations in the TLR3 gene may be found in patients
with type 1 diabetes, Steven-Johnson syndrome, and
toxic epidermal necrolysis [27,29]. In relation to viral
infections, Zhang et al. identified a dominant-negative
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(HSV-1) encephalitis [9], and Bell et al. found a hetero-
zygous mutation (Phe554Ser) associated with impaired
TLR3-dependent interferon induction in response to
HSV-1 [10]. TLR3 polymorphisms have also been found
in Japanese subjects with sub-acute sclerosing panence-
phalitis due to measles virus [11]. In addition, a mis-
sense mutation of TLR3 has been detected in a patient
with influenza-associated encephalopathy [17]. Finally, a
recent study regarding TLR3 polymorphisms and their
association with hepatitis B virus (HBV) infection [18]
found that whereas genetic variance (rs1879026/GT)
was more common in HBV carriers than in uninfected
controls haplotype analysis revealed that specific haplo-
types GCGA (rs1879026, rs5743313, rs5743314, and
rs5743315) were significantly associated with HBV
infection.
This study has the limitation that only a part of the
TLR3 gene was studied, and so it is not possible to es-
tablish whether the presence of other genetic variants
involving TLR3 can explain our findings. However, al-
though based on a partial evaluation of the genetic
characteristics of TLR3, our data add further informa-
tion concerning the relationships between TLR3 and
the development of diseases, and offer further support
for identifying subjects at increased risk of influenza-
related complications, and developing new preventive
and therapeutic measures against influenza. The recent
finding that the administration of a TLR3-mucosal ad-
juvant together with an intranasal influenza vaccine
can significantly improve immune response by indu-
cing cross-protective mucosal immunity against heter-
ologous influenza virus infection is the best
demonstration of how a better knowledge of the role
of innate immunity against influenza viruses can in-
crease our chances of reducing the clinical and socio-
economic impact of this common disease [30-32].
Conclusions
Our findings show that there is a close relationship be-
tween the presence of TLR3 rs5743313/CT and an
increased risk of pneumonia in children infected by the
pandemic A/H1N1/2009 influenza virus, whereas the
prevalence of other selected TLR2, TLR3 and TLR4
polymorphisms does not seem to be associated with an
increased risk of infection.
Methods
Ethics statement
This study was approved by the Institutional Review Board
of Fondazione IRCCS Ca’ Granda Ospedale Maggiore
Policlinico, Milan, Italy, and was carried out in the Depart-
ment of Maternal and Pediatric Sciences of the University
of Milan between 15 October and 30 November 2010. Thewritten informed consent of both parents or a legal
guardian was required, and the older children were asked
to give their assent.
Study subjects
This prospective study involved consecutively enrolled,
otherwise healthy subjects aged less than 15 years who
visited the Emergency Room of the Department because
of an influenza-like illness (ILI) as defined by the Italian
Ministry of Health (http//www.ministerosalute.it): an
acute respiratory disease of sudden onset, with fever (an
axillary temperature of >38°C), accompanied by at least
one of the general symptoms of headache, generalised
malaise, a feverish sensation (sweating and chills) or
asthenia, and one of the respiratory symptoms of
cough, pharyngodynia or nasal congestion. The exclu-
sion criteria were chronic diseases increasing the risk
of complications of viral respiratory infections, including
premature birth; chronic disorders of the pulmonary
or cardiovascular systems, including asthma; chronic
metabolic diseases, including diabetes mellitus; neoplasia;
kidney or liver dysfunction; hemoglobinopathies; im-
munosuppression; diseases requiring long-term aspirin
therapy; and genetic or neurological disorders.
After a complete physical examination, the children
were divided into disease groups on the basis of their
signs and/or symptoms using well-established criteria
[33]. All of the children underwent a chest X-ray, and
the radiological findings were evaluated by an independ-
ent radiologist blinded to the other study variables. The
children with radiographically confirmed pneumonia as
defined by the WHO [34] were hospitalised and consid-
ered as having severe disease. Those with a diagnosis
other than pneumonia were sent home and considered
as having mild disease.
Upon enrolment, a nasopharyngeal sample was col-
lected for the diagnosis of pandemic A/H1N1/2009 in-
fluenza infection, and a blood sample was drawn for
bacterial culture and genetic analysis.
As a control group, a similar number of healthy chil-
dren selected from those consecutively admitted to the
Department for a control examination following minor
surgery during the same study period were genetically
analysed.
Laboratory assays
Identification of A/H1N1 influenza virus
A nasopharyngeal sample was collected from all of the
children using a flexible pernasal flocked swab, and
stored in a mini-tube containing 1 mL of universal
transport medium (UTM-RT Kit Cat. No. 360c, Copan
Italia, Brescia, Italy). The nasopharyngeal samples were
collected from each child by trained pediatricians. The
distance between the patient’s nares and ear lobe was
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the swabs were gently inserted towards the pharynx until
resistance was felt, and then rotated three times to ob-
tain epithelial cells. They were then withdrawn and put
into a tube containing the specific transport medium.
All of the specimens were kept cool and delivered to the
laboratory within three hours of collection. Viral RNA
was extracted by means of a Nuclisens EasyMAG auto-
mated extraction system (bioMeriéux, Bagno a Ripoli,
Florence, Italy) using a generic protocol, a 190 μL sam-
ple input, and 10 μL of cultured phocine distemper virus
(PDV) (the extraction/PCR inhibition control was kindly
provided by Prof. H.G.M. Niesters, UMCG, Groningen,
The Netherland) [31,32]. A real-time polymerase chain
reaction (real-time PCR) to identify A and B influenza
viruses was performed using validated methods that have
been previously described [35]. The primer/probe sets
were: influenza A forward AAGACCAATCCTGT
CACCTCTGA, reverse CAAAGCGTCTACGCTGCA
GTCC, probe FAM-TTTGTGTTCACGCTCACCGTG
CC-BHQ1; influenza B forward GAGACACAATTGCC
TACCTGCTT, reverse TTCTTTCCCACCGAACCAAC,
probe TET-AGAAGATGGAGA AGGCAAAGCAGAA
CTAGC-Eclipse; PDV forward CGGGTGCCTTTTA
CAAGAAC, reverse TTCTTTCCTCAACCTCGTCC,
probe VIC-ATGCAAGGGCCAATTCTTCCAAGTT-
BHQ1. In the case of influenza A-positive samples, the
WHO/CDC protocol was used to characterise pandemic




AGCAGGCA; SWH1 forward GTGCTATAAACACCA
GCCTYCCA; SWH1 reverse CGGGATATTCCTTAA
TCCTGTRGC; SWH1 probe CAGAATATACA’T’ CC
RGTCACAATTGGARAA (‘T’=3’ modified to prevent
extension by TAQ polymerase and linked to BHQ1).
A recombinant plasmid construct carrying the corre-
sponding HA target sequence (kindly provided by Fausto
Baldanti of the Molecular Virology Unit, Fondazione
IRCCS Policlinico San Matteo, Pavia, Italy) was used to
quantify viral load in the influenza A/H1N1/2009-posi-
tive samples. In detail, ten-fold plasmid serial dilutions
ranging from 5 to 5 x 107 input copies were included in
each assay run in order to allow the construction of run-
specific calibration curves that would accurately quantify
viral load in each of the archived samples. The cycle
threshold (Ct) values of each dilution were measured in
duplicate and plotted against the logarithm of their ini-
tial quantities, and the copy numbers in each clinical
sample were derived from the regression line. The quan-
titative results were expressed as RNA copy number/mL
of nasopharyngeal swab following data multiplication by
50 (dilution factor). In order to evaluate reproducibility,intra- and inter-assay standard deviations (SDs) and
coefficients of variation were calculated for each stand-
ard concentration within and between the individual
PCR runs.
Blood cultures
The blood was cultured using a BacT/ALERT (bioMérieux,
Florence, Italy) or BacTec 9240 (Becton Dickinson,
Buccinasco, Italy).
Genotype analyses
The erythrocyte/granulocyte fraction was isolated from
whole blood samples using Histopaque-1077 (Sigma-
Aldrich, Milan, Italy), and genomic DNA was extracted
from this fraction using a Nuclisens EasyMAG auto-
mated extraction system (Biomeriéux), the whole
blood (Specific B) protocol, and a 100 μL sample in-
put volume.
The studied single-nucleotide polymorphisms (SNPs)
were selected on the basis of their previously reported
associations with different diseases, preferably of infec-
tious origin. In the case of the TLR2 and TLR4 genes,
these were non-synonymous SNPs because of their asso-
ciation with tuberculosis (TLR2 Arg753Gln [rs5743708])
[36-38] and respiratory syncytial virus infection (TLR4
Asp299Gly [rs4986790] and TLR4 Thr399Ile [rs4986791])
[13,14]. Two SNPs in the TLR3 gene (intron 3) were
selected because of their proximity to exon 4, a tyrosine-
rich region that is a target site of the tyrosine kinase
c-SRC whose association with TLR3 in dsRNA-containing
endosomes is necessary to initiate antiviral signalling [26].
The SNPs were genotyped on genomic DNA using
pre-designed TaqmanW SNP Genotyping assays, with the
exception of the TLR3 2593 C/T polymorphism, for which
a Custom TaqmanW SNP Genotyping assay (Applied Bio-
systems, Monza, Italy) was designed using the following
primers/probes: 5’-CATTGGTGTCATCCTCCTGAGA-3’
(forward), 5’-GCAGGGCGGCAGAGT-3’ (reverse), VIC-
TCTCCCGACCTCTCC-MGBNFQ (probe 1), FAM-
TCTCCCAACCTCTCC-MGBNFQ (probe 2) (Applied
Biosystems) [36]. The reactions and allelic discrimin-
ation analyses were performed using an ABI PRISM
7000 sequence detection system (Applied Biosystems).
Reference samples for each genotype were included in
all of the reaction plates, and the genotypes were con-
firmed by sequencing.
Statistical analyses
The data were analysed using SAS for Windows v. 9.1
(SAS Institute, Cary, NC, USA). The continuous vari-
ables are given as mean values ± standard deviation, and
were analysed using a non-parametric test (i.e. the two-
sided Wilcoxon’s rank-sum test) as they were not nor-
mally distributed (on the basis of the Shapiro-Wilk
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and percentages, and were analysed using contingency
tables and the chi-squared or Fisher’s test, as appropri-
ate. Allele and genotype frequencies were calculated by
direct counting. In order to investigate Hardy-Weinberg
equilibrium (HWE), we computed the expected numbers
of different genotypes under HWE and compared them
with the observed numbers, and then assessed potential
deviations using chi-squared tests.
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